12 June, 2017
State Street Corporation has 5.72 million shares. Kcg holds 0.01% of its portfolio in Amicus Therapeutics, Inc. Millennium Mngmt Limited accumulated 126,091 shares or 0% of the stock. Cordasco Fincl reported 0% of its portfolio in Amicus Therapeutics, Inc. Edge Wealth Mgmt Limited Liability has invested 0% of its portfolio in Amicus Therapeutics, Inc.
Stock market analysts and brokers have recently amended their target prices on shares of Amicus Therapeutics, Inc. Amicus Therapeutics (NASDAQ:FOLD)'s price to free cash flow for trailing twelve months is 0. (NASDAQ:FOLD). 142,703 were reported by Bancorp Of America De.
The share price of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Monday, August 31 with "Buy" rating. Cibc Asset Mngmt Incorporated, a Ontario - Canada-based fund reported 235,705 shares. The company's shares performance for the last one month was 26.39% and 22.97% in the previous week. Following the completion of the transaction, the insider now owns 474,438 shares in the company, valued at $3,795,504. More interesting news about Amicus Therapeutics, Inc.
Since December 22, 2016, it had 4 insider buys, and 5 insider sales for $1.26 million activity. 94,750 shares were bought by PERCEPTIVE ADVISORS LLC, worth $470,055 on Friday, December 30. PERCEPTIVE ADVISORS LLC bought $470,055 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 145,300 shares. Shares for $392,400 were sold by Campbell Bradley L on Thursday, March 2.
Pacifica Capital Investments Llc decreased Us Bancorp Del (USB) stake by 14.59% reported in 2016Q4 SEC filing.
Discovery Communications, Inc. (NASDAQ:DISCA) has a market cap of $10 billion and over the last 12 months, DISCA has declined by -9.42%.
For a company of Amicus' size and current developmental state, investors probably weren't focused so much on its net loss of $55 million for quarter as they were on the company's progress on the clinical, regulatory, and commercialization fronts. The stock rose 1.82% or $0.93 reaching $52.07. About 391,734 shares traded.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, May 9th. It has underperformed by 4.25% the S&P500.
Perceptive Advisors Llc, which manages about $2.09 billion and $1.41 billion US Long portfolio, decreased its stake in Ophthotech Corp Put 20 01/20/2017 (Put) (NASDAQ:OPHT) by 598,400 shares to 1,600 shares, valued at $24,000 in 2016Q4, according to the filing. It also reduced its holding in Blueprint Medicines by 186,204 shares in the quarter, leaving it with 273,820 shares, and cut its stake in Supernus Pharmaceuticals (NASDAQ:SUPN). Norges Bank purchased a new position in shares of Amicus Therapeutics during the fourth quarter worth about $5,064,000. Amicus Therapeutics presently has an average rating of "Buy" and a consensus price target of $11.18. $150,000 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was released by: Globenewswire.com and their article: "Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101 for ..." with publication date: May 31, 2017. Therefore 86% are positive. (FOLD) is $12.92/share according to the consensus of analysts working on the stock, with an expected EPS of $-0.36/share for the current quarter. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a "strong sell" rating to a "sell" rating in a report on Friday, June 2nd. The stock is now trading 13.01% above its SMA 50 and 22.01% above its SMA 200. The stock of Amicus Therapeutics, Inc. The stock has "Buy" rating by Janney Capital on Tuesday, March 8. On Tuesday, September 8 the stock rating was maintained by JP Morgan with "Overweight". (NASDAQ:FOLD) rating on Tuesday, September 8. The rating was maintained by FBR Capital on Monday, November 28 with "Outperform". Robert W. Baird reissued an "outperform" rating and issued a $12.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a research report on Wednesday, May 17th. On Thursday, April 14 the stock rating was initiated by Robert W. Baird with "Neutral". The company was maintained on Monday, October 5 by Leerink Swann. The firm has "Buy" rating by Cowen & Co given on Tuesday, September 1.